DUBLIN, Feb. 13, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2023 financial results on Tuesday, February 27th, 2024 and will host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or b ...

Perrigo Company Plc (NYSE:PRGO) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Susan Anderson - Canaccord Genuity Daniel Biolsi - Hedgeye Keonhee Kim - Morning Star Operator Good Day and welcome to the Perrigo Third Quarter 2023 Financial Results Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q _______________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36353 Perrigo Company plc (Exact name ...

Adding HR photos ...

Perrigo Company plc (NYSE:PRGO) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Alec Legg - Canaccord Genuity Daniel Biolsi - Hedgeye Operator Good Day and welcome to the Perrigo Second Quarter 2023 Financial Results Conference Call. All participants w ...

Perrigo Company plc. (NYSE:PRGO) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Murray Kessler - President, Chief Executive Officer Eduardo Bezerra - Executive Vice President, Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Genuity Ethan Brown - JPMorgan Daniel Biolsi - Hedgeye Operator Good morning and welcome to the Perrigo First Quarter 2023 Financial Results Conference Call. All participants wi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-36353 Perrigo Company plc (Exact name of registrant as specified in its charter) Ireland N/A (State or other jurisdiction of incorpo ...

Financial Data and Key Metrics Changes - Perrigo reported a constant currency net sales increase of 12% in Q3 2022 and 14% year-to-date, with organic net sales growth of 8% in the quarter and 11% year-to-date, exceeding the long-term target of 3% [8][9] - Constant currency diluted EPS for the quarter was $0.65, up 44% year-over-year, despite higher interest expenses and a slightly increased share count [9][24] - Gross margin increased by 210 basis points year-over-year, contributing to a constant currency adjusted operating income growth of 32% [9][25] Business Line Data and Key Metrics Changes - Women's health sales grew 100% due to the addition of HRA brands, driven by increased demand for emergency contraception [10] - Skincare sales increased by 28%, while upper respiratory sales grew by 19% due to higher instances of cough and cold in Europe [11] - Nutrition business saw an 18% increase, driven by heightened infant formula demand amid a national brand shortage [12] Market Data and Key Metrics Changes - Perrigo gained market share across all US business units and major categories, with significant gains in e-commerce and store brands [8][14] - The total US OTC market growth slowed to 2.3% in the latest 13 weeks, while Perrigo's retail growth was up 5.8% [15] - The company expects unfavorable currency translation to impact full-year 2022 net sales by approximately $230 million [16] Company Strategy and Development Direction - The integration of HRA remains a cornerstone of Perrigo's growth strategy, with total synergy estimates raised to €50 million by the end of 2024 [17][31] - The company is focused on reducing leverage, aiming for around 3x net leverage by the end of 2024, while continuing to invest in supply chain initiatives [67][69] - Strategic pricing actions and cost-saving measures are being implemented to offset inflationary pressures [16][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by inflation and macroeconomic factors but expressed confidence in achieving 2023 financial goals [7][22] - The company remains optimistic about its fundamentals, with expectations for gross margin expansion and market share growth [22][73] - Management indicated that the supply chain reinvention program is expected to deliver significant incremental operating income in 2023 [19] Other Important Information - Perrigo's cash on the balance sheet was $469 million at the end of Q3, down from $485 million at the end of Q2 [29] - The company invested $70 million in capital expenditures and returned $107 million to shareholders through dividends in the first nine months of the year [30] Q&A Session Summary Question: Can you provide details on the Gateway acquisition's revenue run rate and its impact on capacity? - Management indicated that the Gateway acquisition will significantly enhance capacity and is expected to contribute to operating income [35][39] Question: How did the HRA business perform relative to expectations? - The HRA business is performing as planned, with a gross margin impact of over 200 basis points in the quarter [41][42] Question: What is the outlook for gross margins in 2023? - Management expects gross margins to improve, with recovery from previous freight cost increases and ongoing supply chain initiatives [50][52] Question: How will operating expenses trend going forward? - A slight increase in operating expenses is anticipated in Q4 due to seasonal factors and increased promotional activities [46] Question: What are the capital allocation priorities moving forward? - The primary focus is on reducing leverage while continuing to invest in strategic initiatives that yield significant operating income returns [67][69]

Financial Data and Key Metrics Changes - The company reported a consolidated GAAP loss from continuing operations of $65 million for Q2 2022, translating to a loss of $0.48 per diluted share. Adjusted net income from continuing operations was $59 million, with adjusted diluted EPS at $0.43, or $0.49 on a constant currency basis, compared to $0.50 in the prior year quarter [28][29] - Net sales increased by 14.3%, with organic net sales growing by 17.2%, driven by strong consumer demand [30] - Gross profits grew by 8.7%, or 17% on a constant currency basis, despite inflationary pressures [30] Business Line Data and Key Metrics Changes - Consumer Self Care Americas (CSCA) net sales increased by 17%, driven by strong demand for cough and cold products and nutrition [32] - The Consumer Self Care International (CSCI) segment saw net sales increase by 25.8% on a constant currency basis, with organic net sales growing by 10.6% [33] - The women's health business grew by 77%, primarily due to the addition of HRA businesses and increased demand related to recent judicial decisions in the U.S. [14] Market Data and Key Metrics Changes - The upper respiratory revenues grew by 44% globally, attributed to a rebound in cough-cold sales compared to the previous year [13] - The nutrition business saw a 31% increase, primarily driven by infant formula demand due to a competitor's recall [14] - E-commerce sales grew more than 25% in the first half of the year, now accounting for over 12% of global sales [17] Company Strategy and Development Direction - The company is focused on optimizing and accelerating its self-care strategy, with plans to integrate the HRA portfolio and achieve related cost synergies [24] - A global supply chain initiative is underway, aiming for $100 million to $300 million in net cost savings over five years [20][22] - The company is expanding its product categories to include women's health and skin care, with skin care now being the second largest global category [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing challenges from inflation and labor shortages but expressed confidence in achieving gross margin recovery [19][43] - The company anticipates continued strong demand for its products, particularly in the context of the upcoming cough-cold season [48] - Management remains optimistic about the future, highlighting a strong pipeline of innovation and the successful execution of their self-care strategy [64] Other Important Information - The company closed on a $2.6 billion senior secured credit facility, locking in favorable rates [8] - The FDA approved the first-ever branded Rx to OTC switch for Nasonex, marking a significant regulatory achievement [18] - The company is committed to maintaining its dividend growth, with a strong track record of 18 consecutive years of increases [35] Q&A Session Summary Question: Update on trade inventory levels and growth outlook - Management confirmed that inventory levels are appropriate, with no significant influence on business going forward [39][40] Question: Comments on gross margin expectations - Management indicated that costs have continued to rise, but they remain on track to achieve their gross margin recovery goals [45] Question: Impact of recession on business - Management noted a more balanced portfolio now, with a shift towards store brands benefiting from potential downtrading during a recession [60] Question: Update on HRA deal accretion - Management confirmed that the $150 million operating profit impact from the HRA acquisition remains on track, though currency adjustments may affect it [62]

Perrigo Company plc (NYSE:PRGO) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bradley Joseph - Vice President of Investor Relations Murray Kessler - President and Chief Executive Officer Raymond Silcock - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Elliot Wilbur - Raymond James Operator Good day and welcome to the Perrigo First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instruction ...